

Hikma and GSK agree to cease potential acquisition discussions in Egypt and Tunisia

London, 11 March 2021 – On 26 January 2021, Hikma Pharmaceuticals PLC (Hikma) announced that it had entered into a non-binding term sheet with GlaxoSmithKline PLC (GSK) for the purposes of potentially acquiring GSK's pharmaceutical and consumer businesses in Egypt and its pharmaceutical business in Tunisia (the Proposed Transaction).

Hikma today confirms that both companies have agreed to cease discussions regarding the Proposed Transaction and, accordingly, Hikma will not be launching a Mandatory Tender Offer process to acquire the shares in GlaxoSmithKline SAE Egypt.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 7776 477050
uk-investors@hikma.uk.com

Layan Kalisse
Investor Relations Analyst

+44 (0)20 7399 2788 / +44 (0)7970 709912

Mona Abdallah
Communication Director - MENA

+962 7 96777710
mena_communications@hikma.com

Teneo (Press):

Charles Armitstead/ Camilla Cunningham

+44 (0)7703 330 269/ +44 (0)7464 982 426

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com